Chemically modified bovine beta-lactoglobulin inhibits human papillomavirus infection

Microbes Infect. 2013 Jun;15(6-7):506-10. doi: 10.1016/j.micinf.2013.03.003. Epub 2013 Mar 19.

Abstract

Previous studies have shown that 3-hydroxyphthalic anhydride-modified bovine beta-lactoglobulin is a promising anti-HIV microbicide candidate. Here we found that this chemically modified protein, designated JB01, exhibited highly potent antiviral activity against infection by human papillomaviruses (HPV), including HPV6, HPV16 and HPV18. Its anti-HPV activity was correlated with the percentage of modified lysine and arginine residues in JB01. This modified milk protein had no cytotoxicity at the concentration of 1 mg/ml, and it is highly stable at room temperature and 37 °C for at least 12 weeks. These results suggest that JB01 has good potential to be developed as an effective, safe and inexpensive antiviral agent for treatment and prevention of HPV infection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antiviral Agents / chemistry
  • Antiviral Agents / pharmacology*
  • Antiviral Agents / toxicity
  • Cattle
  • Cell Line
  • Cell Survival / drug effects
  • Human papillomavirus 16 / drug effects*
  • Human papillomavirus 16 / growth & development
  • Human papillomavirus 18 / drug effects*
  • Human papillomavirus 18 / growth & development
  • Human papillomavirus 6 / drug effects*
  • Human papillomavirus 6 / growth & development
  • Humans
  • Inhibitory Concentration 50
  • Lactoglobulins / chemistry
  • Lactoglobulins / pharmacology*
  • Lactoglobulins / toxicity
  • Phthalic Anhydrides / chemistry
  • Phthalic Anhydrides / pharmacology*
  • Phthalic Anhydrides / toxicity
  • Protein Stability
  • Structure-Activity Relationship
  • Temperature
  • Time Factors

Substances

  • Antiviral Agents
  • Lactoglobulins
  • Phthalic Anhydrides
  • 3-hydroxyphthalic anhydride